RT Journal Article
SR Electronic
T1 Therapeutic effectpredictors during sublingual immunotherapy for Japanese seasonal allergic rhinitis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3470
VO 44
IS Suppl 58
A1 Takechiyo Yamada
A1 Masafumi Sakashita
A1 Yoshimasa Imoto
A1 Shigeharu Fujieda
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3470.abstract
AB Japanese seasonal allergic rhinitis (JSAR) differs markedly from other pollen allergies, and is characteristic to our country, what it recently called “national affliction” in Japan. Antigen-specific immunotherapy can change the natural course of AR and is recognized as a curative treatment against type I allergy without impaired performance. Recently, in Japan, sublingual immunotherapy (SLIT) has been developed and has become a safer and more beneficial immunotherapy for JSAR.We have continued the SLIT for the patients of Japanese cedar pollinosis for several years, symptom medication scores were observed during the peak of high-pollen season. The levels of thirteen cytokines, chemokines, or integrin ligands including thymic stromal lymphopoietin (TSLP) in the serum were assessed using an ELISA kits or multiple assay kits.The levels of TSLP and IL17A in the serum (year 4) significantly decreased during SLIT, and correlated with symptom scores during SLIT (year 4).The levels of TSLP in the serum correlate with symptom scores during SLIT (year 1).The TSLP-levels in the serum of year 1 correlate with the symptom scores of year 4 during SLIT.The insights that have been provided over the last few years concerning the regulation of TSLP expression and production will have a marked impact on therapeutic interventions for inflammatory responses and allergic reactions.These suggest that SLIT modulates Th2 profile, and the level of serum TSLP could be one of the biomarkers or therapeutic effectpredictorsof the effectiveness of SLIT for JSAR.